A neuroendocrine neoplasm that involves the bronchus.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Documentation regarding bronchial endocrine tumors is limited primarily due to their rarity. Conditions affecting fewer than 200,000 individuals in the U.S. often lack extensive clinical studies, leading to gaps in understanding their genetic underpinnings and optimal management strategies. The complexity of neuroendocrine tumors and their overlapping phenotypes with other conditions further complicate the clinical characterization.
The clinical presentation of bronchial endocrine tumors typically includes a range of respiratory and systemic symptoms. The most consistently reported feature is the presence of pulmonary carcinoid tumors. Other common symptoms, occurring in 30-79% of patients, include weight loss, nonproductive cough, chest pain, anorexia, pneumonia, dyspnea, asthma, hemoptysis, and chronic noninfectious lymphadenopathy. These symptoms can significantly impact quality of life and may require a multidisciplinary approach for management.
To navigate your care effectively, consider consulting with a specialist in thoracic oncology or a pulmonologist with experience in neuroendocrine tumors. These professionals can provide tailored management strategies and may have insights into ongoing clinical trials. Additionally, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information. While no specific patient organizations are identified for this condition, engaging with broader cancer support networks may provide community and resources. Exploring participation in clinical trials could also be beneficial.
Currently, there are 180 active clinical trials related to bronchial endocrine tumors. These trials may explore various treatment options and therapeutic approaches, providing hope for patients seeking new management strategies. You can find more information about these trials at ClinicalTrials.gov by searching for 'bronchial endocrine tumor'. Participation in these studies may offer access to cutting-edge therapies and contribute to advancing our understanding of this condition.
Actionable guidance for navigating care for bronchial endocrine tumor
To navigate your care effectively, consider consulting with a specialist in thoracic oncology or a pulmonologist with experience in neuroendocrine tumors. These professionals can provide tailored management strategies and may have insights into ongoing clinical trials. Additionally, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information. While no specific patient organizations are identified for this condition, engaging with broader cancer support networks may provide community and resources. Exploring participation in clinical trials could also be beneficial.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease